The trajectory of Sildenafil presents a nuanced case for stakeholders in the medicinal sector. While initially a phenomenal success, creating huge profits, the intellectual property lapse and the subsequent entry of off-brand competitors have considerably changed income. This raises questions about the ongoing sustainability of analogous medication